Wall Street analysts who follow the pharmaceutical sector believe the risk is minimal and that Lipitor atorvastatin generic lipitor will enjoy patent protection through the end of its patent life in 2011. This new analysis of patients with acute coronary syndrome is consistent with the health Atorvastatin generic lipitor economic findings of the overall IDEAL trial of 8,888 patients. And Atorvastatin generic lipitor laboratorios Belmac S. , and is one of four separate challenges to the enantiomer patent by generic companies in Spain.
"One of these analyses suggests that even with the availability of low cost generics, intensive Lipitor therapy is a good economic value," said Dr. PhyzioType(TM) Clinical Management Systems are composed of an ensemble of inherited DNA markers genotyped by arrays and interpreted Atorvastatin generic lipitor by a biomathematical algorithm in order to convey to physicians predicted comparisons of side effect risk among drugs for the individual patient. * This finding resulted from a significant 15 percent reduction in both cardiovascular hospitalizations and a significant 27 percent reduction in revascularizations. Researchers at the Division of Cardiology of Hartford Hospital and at the Department of Laboratory Medicine, University of California San Francisco, were co-authors of the publication and are co-investigators in the grant, which also includes the Rogosin Institute. Ranbaxy vice president Charles Caprariello said the company would appeal the ruling that upheld the main patent. Under the atorvastatin generic lipitor sbir program, Genomas will integrate the clinical expertise of its strategic partner, Hartford Hospital, with the company's proprietary physiogenomics technology to develop DNA-guided clinical management systems that predict and compare an individual's risk of SINM from statin medications.
The grant, entitled "DNA Diagnostic System for Statin Safety and Efficacy," was awarded by the National Institute of General Medical Sciences (NIGMS). That decision, which is also subject to possible appeal, prevents Ranbaxy from launching a competitor drug before November 2011. Case is more important because of the economic implications, said Catherine Arnold, an analyst at Credit Suisse First Boston. The patent was challenged atorvastatin generic lipitor jointly by generic companies Laboratorios Cinfa S. , Kern Pharma S. , Laboratorios Alter S. Had challenged both patents, and was joined by Britain's Arrow Generics Ltd. "As physicians, payers and employers come under increasing pressure to reduce medical healthcare costs, this analysis provides them with additional support for offering intensive Lipitor therapy to help achieve improved and cost-effective cardiovascular outcomes for their patients," said Dr. The patent atorvastatin generic lipitor (ep 409,281) had been challenged by generics manufacturer Ranbaxy and expires in July 2010. Ranbaxy has brought a suit against two Lipitor patents in the atorvastatin generic lipitor united States, where $6. 6 billion, or about 61 percent, of the drug's sales are generated. About the Overall IDEAL Trial IDEAL was an open-label trial of 8,888 patients Atorvastatin generic lipitor who had had a previous heart attack comparing Lipitor 80 mg with simvastatin 20 mg-40 mg. In this study, patients taking Lipitor 80 mg had a significant 22 percent reduction in the risk of major cardiovascular events over and above patients taking Lipitor 10 mg.